The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score

Authors


Meinrad Gawaz, Medizinische Klinik III, University Hospital Tübingen, Otfried-Müller-Strasse 10, 72076 Tübingen, Germany.
Tel.: +49 7071 2983688; fax: +49 7071 295749; e-mail: meinrad.gawaz@med.uni-tuebingen.de

Abstract

Summary. Background: Recent studies suggest a high interindividual variability of response to clopidogrel associated with adverse cardiovascular outcome. Different clinical factors are considered to influence a persistent residual platelet aggregation (RPA) despite conventional antiplatelet therapy.

Objectives: To investigate clinical factors that affect RPA after 600-mg clopidogrel loading in a large unselected cohort of patients with symptomatic CAD.

Methods: The study population included a consecutive cohort of 1092 patients treated with coronary stenting for stable angina and acute coronary syndromes (ACS). Residual platelet activity was assessed by ADP (20 μmol L−1)-induced platelet aggregation ≥ 6 h after LD. Eleven clinical factors were included in the primary analysis.

Results: In multivariate regression analysis increased RPA was significantly influenced by ACS, reduced LV-function, diabetes mellitus, renal failure (creatinine > 1.5 mg dL−1), and age > 65 years. In a factor-weighed model the risk for high RPA increased with higher score levels (OR for patients with a score of 1–3, 1.21, 95% CI 0.7–2.1; score 4–6, OR 2.0, 95% CI 1.17–3.5; = 0.01; score 7–9, OR 3.3, 95% CI 1.8–6.0). During a 30-day follow-up the incidence of major adverse events was higher in patients with RPA in the upper tertile (4.8% vs. 2.5% in the 2nd and 1.5% in the 1st tertile; < 0.05).

Conclusions: The PREDICT score provides a good tool to estimate residual platelet activity after clopidogrel LD by easily available patient details. Additionally, we demonstrate its association with short-term outcome. Thus, patients with a high score may benefit from intensified antiplatelet therapy by improved platelet inhibition and risk reduction for thromboischemic events.

Ancillary